Nyxoah (NASDAQ:NYXH) Stock Price Down 4.6% on Disappointing Earnings

Nyxoah SA (NASDAQ:NYXH)’s stock price fell 4.6% during trading on Tuesday after the company announced weaker than expected quarterly earnings. The stock traded as low as $6.27 and last traded at $6.27. 242,912 shares were traded during trading, an increase of 63% from the average session volume of 149,328 shares. The stock had previously closed at $6.57.

The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Nyxoah had a negative net margin of 1,541.84% and a negative return on equity of 79.18%. The company had revenue of $1.58 million for the quarter, compared to analyst estimates of $1.33 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vestal Point Capital LP bought a new position in Nyxoah during the fourth quarter valued at approximately $23,394,000. Franklin Resources Inc. raised its position in Nyxoah by 0.9% in the second quarter. Franklin Resources Inc. now owns 294,990 shares of the company’s stock valued at $2,207,000 after purchasing an additional 2,655 shares during the period. Kovack Advisors Inc. increased its holdings in Nyxoah by 148.2% in the second quarter. Kovack Advisors Inc. now owns 57,827 shares of the company’s stock valued at $433,000 after buying an additional 34,532 shares during the last quarter. Shay Capital LLC acquired a new stake in shares of Nyxoah during the second quarter worth about $374,000. Finally, Renaissance Technologies LLC purchased a new position in Nyxoah in the fourth quarter valued at about $187,000.

Nyxoah Stock Performance

The firm has a market capitalization of $215.94 million, a PE ratio of -2.76 and a beta of 1.61. The stock’s 50 day moving average price is $7.49 and its two-hundred day moving average price is $7.95. The company has a current ratio of 2.63, a quick ratio of 3.35 and a debt-to-equity ratio of 0.29.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.